Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -1.32 Decreased by -73.68% | -1.49 Increased by +11.41% |
| Aug 8, 24 | -1.56 Decreased by -85.71% | -1.38 Decreased by -13.04% |
| May 9, 24 | -1.42 Decreased by -59.55% | -1.31 Decreased by -8.40% |
| Mar 7, 24 | -1.39 Decreased by -4.51% | -1.08 Decreased by -28.70% |
| Nov 9, 23 | -0.76 Increased by +42.42% | -0.89 Increased by +14.61% |
| Aug 10, 23 | -0.84 Increased by +36.84% | -0.98 Increased by +14.29% |
| May 10, 23 | -0.89 Increased by +16.82% | -1.26 Increased by +29.37% |
| Feb 28, 23 | -1.33 Decreased by -40.00% | -1.35 Increased by +1.48% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 16.35 M Increased by +N/A% | -85.58 M Decreased by -97.90% | Decreased by -523.34% Decreased by N/A% |
| Jun 30, 24 | 7.32 M Increased by +N/A% | -91.45 M Decreased by -123.23% | Decreased by -1.25 K% Decreased by N/A% |
| Mar 31, 24 | 1.91 M Increased by +N/A% | -82.85 M Decreased by -119.95% | Decreased by -4.33 K% Decreased by N/A% |
| Dec 31, 23 | 682.00 K Increased by +N/A% | -79.57 M Decreased by -25.40% | Decreased by -11.67 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -43.24 M Increased by +27.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -40.97 M Increased by +27.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -37.67 M Increased by +13.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -63.45 M Decreased by -77.11% | Decreased by N/A% Decreased by N/A% |